158 related articles for article (PubMed ID: 38758238)
1. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
[TBL] [Abstract][Full Text] [Related]
2. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
3. Epigenomic and somatic mutations of pituitary tumors with clinical and pathological correlations in 111 patients.
Guaraldi F; Morandi L; Zoli M; Mazzatenta D; Righi A; Evangelisti S; Ambrosi F; Tonon C; Giannini C; Lloyd RV; Asioli S
Clin Endocrinol (Oxf); 2022 Dec; 97(6):763-772. PubMed ID: 36161330
[TBL] [Abstract][Full Text] [Related]
4. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
6. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
7. DNA Methylation of Tumor Suppressor Genes in Pituitary Neuroendocrine Tumors.
García-Martínez A; Sottile J; Sánchez-Tejada L; Fajardo C; Cámara R; Lamas C; Barberá VM; Picó A
J Clin Endocrinol Metab; 2019 Apr; 104(4):1272-1282. PubMed ID: 30423170
[TBL] [Abstract][Full Text] [Related]
8. Aggressive pituitary tumors (PitNETs).
Nishioka H
Endocr J; 2023 Mar; 70(3):241-248. PubMed ID: 36858483
[TBL] [Abstract][Full Text] [Related]
9. Aggressive nonfunctioning pituitary neuroendocrine tumors.
Portovedo S; Neto LV; Soares P; Carvalho DP; Takiya CM; Miranda-Alves L
Brain Tumor Pathol; 2022 Oct; 39(4):183-199. PubMed ID: 35725837
[TBL] [Abstract][Full Text] [Related]
10. Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations.
Casar-Borota O; Boldt HB; Engström BE; Andersen MS; Baussart B; Bengtsson D; Berinder K; Ekman B; Feldt-Rasmussen U; Höybye C; Jørgensen JOL; Kolnes AJ; Korbonits M; Rasmussen ÅK; Lindsay JR; Loughrey PB; Maiter D; Manojlovic-Gacic E; Pahnke J; Poliani PL; Popovic V; Ragnarsson O; Schalin-Jäntti C; Scheie D; Tóth M; Villa C; Wirenfeldt M; Kunicki J; Burman P
J Clin Endocrinol Metab; 2021 Mar; 106(4):1183-1194. PubMed ID: 33106857
[TBL] [Abstract][Full Text] [Related]
11. Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors.
Guo X; Yang Y; Qian Z; Chang M; Zhao Y; Ma W; Wang Y; Xing B
Cancer Lett; 2024 Jun; 592():216908. PubMed ID: 38677640
[TBL] [Abstract][Full Text] [Related]
12. Distribution of E- and N-cadherin in subgroups of non-functioning pituitary neuroendocrine tumours.
Øystese KAB; Casar-Borota O; Berg-Johnsen J; Berg JP; Bollerslev J
Endocrine; 2022 Jun; 77(1):151-159. PubMed ID: 35674926
[TBL] [Abstract][Full Text] [Related]
13. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
14. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
15. Frequency and Role of CDKN2A Deletion in High-Risk Pituitary Neuroendocrine Tumors.
Kara M; Tokat F; Pamir MN; Danyeli AE
Endocr Pathol; 2020 Jun; 31(2):166-173. PubMed ID: 32157655
[TBL] [Abstract][Full Text] [Related]
16. Detection of tumor-specific DNA methylation markers in the blood of patients with pituitary neuroendocrine tumors.
Herrgott GA; Asmaro KP; Wells M; Sabedot TS; Malta TM; Mosella MS; Nelson K; Scarpace L; Barnholtz-Sloan JS; Sloan AE; Selman WR; deCarvalho AC; Poisson LM; Mukherjee A; Robin AM; Lee IY; Snyder J; Walbert T; Rosenblum M; Mikkelsen T; Bhan A; Craig J; Kalkanis S; Rock J; Noushmehr H; Castro AV
Neuro Oncol; 2022 Jul; 24(7):1126-1139. PubMed ID: 35212383
[TBL] [Abstract][Full Text] [Related]
17. PITX2 Expression in Non-functional Pituitary Neuroendocrine Tumor with Cavernous Sinus Invasion.
Tamura R; Ohara K; Morimoto Y; Kosugi K; Oishi Y; Sato M; Yoshida K; Toda M
Endocr Pathol; 2019 Jun; 30(2):81-89. PubMed ID: 30903445
[TBL] [Abstract][Full Text] [Related]
18. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
19. Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.
Spada A; Mantovani G; Lania AG; Treppiedi D; Mangili F; Catalano R; Carosi G; Sala E; Peverelli E
Neuroendocrinology; 2022; 112(1):15-33. PubMed ID: 33524974
[TBL] [Abstract][Full Text] [Related]
20. [Epidemiology, Genetics and Pathogenesis of Pituitary Neuroendocrine Tumors].
Suzuki K; Tahara S
No Shinkei Geka; 2023 Jul; 51(4):593-606. PubMed ID: 37491056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
